594 related articles for article (PubMed ID: 22178561)
1. Glycans as cancer biomarkers.
Adamczyk B; Tharmalingam T; Rudd PM
Biochim Biophys Acta; 2012 Sep; 1820(9):1347-53. PubMed ID: 22178561
[TBL] [Abstract][Full Text] [Related]
2. Aberrant glycosylation as biomarker for cancer: focus on CD43.
Tuccillo FM; de Laurentiis A; Palmieri C; Fiume G; Bonelli P; Borrelli A; Tassone P; Scala I; Buonaguro FM; Quinto I; Scala G
Biomed Res Int; 2014; 2014():742831. PubMed ID: 24689054
[TBL] [Abstract][Full Text] [Related]
3. Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.
Ferdosi S; Rehder DS; Maranian P; Castle EP; Ho TH; Pass HI; Cramer DW; Anderson KS; Fu L; Cole DEC; Le T; Wu X; Borges CR
J Proteome Res; 2018 Jan; 17(1):543-558. PubMed ID: 29129073
[TBL] [Abstract][Full Text] [Related]
4. The Repertoire of Glycan Alterations and Glycoproteins in Human Cancers.
Kori M; Aydin B; Gulfidan G; Beklen H; Kelesoglu N; Caliskan Iscan A; Turanli B; Erzik C; Karademir B; Arga KY
OMICS; 2021 Mar; 25(3):139-168. PubMed ID: 33404348
[TBL] [Abstract][Full Text] [Related]
5. Glycomics and glycoproteomics focused on aging and age-related diseases--Glycans as a potential biomarker for physiological alterations.
Miura Y; Endo T
Biochim Biophys Acta; 2016 Aug; 1860(8):1608-14. PubMed ID: 26801879
[TBL] [Abstract][Full Text] [Related]
6. Glycoproteomic strategies: From discovery to clinical application of cancer carbohydrate biomarkers.
Ueda K
Proteomics Clin Appl; 2013 Oct; 7(9-10):607-17. PubMed ID: 23640819
[TBL] [Abstract][Full Text] [Related]
7. Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women.
Gebrehiwot AG; Melka DS; Kassaye YM; Gemechu T; Lako W; Hinou H; Nishimura SI
BMC Cancer; 2019 Jun; 19(1):588. PubMed ID: 31208374
[TBL] [Abstract][Full Text] [Related]
8. A serum glycomics approach to breast cancer biomarkers.
Kirmiz C; Li B; An HJ; Clowers BH; Chew HK; Lam KS; Ferrige A; Alecio R; Borowsky AD; Sulaimon S; Lebrilla CB; Miyamoto S
Mol Cell Proteomics; 2007 Jan; 6(1):43-55. PubMed ID: 16847285
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.
Kyselova Z; Mechref Y; Kang P; Goetz JA; Dobrolecki LE; Sledge GW; Schnaper L; Hickey RJ; Malkas LH; Novotny MV
Clin Chem; 2008 Jul; 54(7):1166-75. PubMed ID: 18487288
[TBL] [Abstract][Full Text] [Related]
10. Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples.
Hecht ES; Scholl EH; Walker SH; Taylor AD; Cliby WA; Motsinger-Reif AA; Muddiman DC
J Proteome Res; 2015 Oct; 14(10):4394-401. PubMed ID: 26347193
[TBL] [Abstract][Full Text] [Related]
11. Isomer-specific profiling of N-glycans derived from human serum for potential biomarker discovery in pancreatic cancer.
Liu Y; Wang C; Wang R; Wu Y; Zhang L; Liu BF; Cheng L; Liu X
J Proteomics; 2018 Jun; 181():160-169. PubMed ID: 29674015
[TBL] [Abstract][Full Text] [Related]
12. Glycoblotting method allows for rapid and efficient glycome profiling of human Alzheimer's disease brain, serum and cerebrospinal fluid towards potential biomarker discovery.
Gizaw ST; Ohashi T; Tanaka M; Hinou H; Nishimura S
Biochim Biophys Acta; 2016 Aug; 1860(8):1716-27. PubMed ID: 26968461
[TBL] [Abstract][Full Text] [Related]
13. Mass Spectrometry-Based N-Glycomics of Colorectal Cancer.
Sethi MK; Fanayan S
Int J Mol Sci; 2015 Dec; 16(12):29278-304. PubMed ID: 26690136
[TBL] [Abstract][Full Text] [Related]
14. Glycosylation and cancer: moving glycomics to the forefront.
Drake RR
Adv Cancer Res; 2015; 126():1-10. PubMed ID: 25727144
[TBL] [Abstract][Full Text] [Related]
15. A glycomics approach to the discovery of potential cancer biomarkers.
An HJ; Lebrilla CB
Methods Mol Biol; 2010; 600():199-213. PubMed ID: 19882130
[TBL] [Abstract][Full Text] [Related]
16. UniCarbKB: New database features for integrating glycan structure abundance, compositional glycoproteomics data, and disease associations.
Campbell MP; Packer NH
Biochim Biophys Acta; 2016 Aug; 1860(8):1669-75. PubMed ID: 26940363
[TBL] [Abstract][Full Text] [Related]
17. Systems Glycobiology: Integrating Glycogenomics, Glycoproteomics, Glycomics, and Other 'Omics Data Sets to Characterize Cellular Glycosylation Processes.
Bennun SV; Hizal DB; Heffner K; Can O; Zhang H; Betenbaugh MJ
J Mol Biol; 2016 Aug; 428(16):3337-3352. PubMed ID: 27423401
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and Prognostic Performance of Blood Plasma Glycan Features in the Women Epidemiology Lung Cancer (WELCA) Study.
Hu Y; Ferdosi S; Kapuruge EP; Diaz de Leon JA; Stücker I; Radoï L; Guénel P; Borges CR
J Proteome Res; 2019 Nov; 18(11):3985-3998. PubMed ID: 31566983
[TBL] [Abstract][Full Text] [Related]
19. Human disease glycomics: technology advances enabling protein glycosylation analysis - part 2.
Everest-Dass AV; Moh ESX; Ashwood C; Shathili AMM; Packer NH
Expert Rev Proteomics; 2018 Apr; 15(4):341-352. PubMed ID: 29521143
[TBL] [Abstract][Full Text] [Related]
20. Methods for the absolute quantification of N-glycan biomarkers.
Etxebarria J; Reichardt NC
Biochim Biophys Acta; 2016 Aug; 1860(8):1676-87. PubMed ID: 26953846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
